Northwest Biotherapeutics, Inc.
NWBOW
NWBOW was delisted on the 16th of December, 2016.
1 hedge funds and large institutions have $2K invested in Northwest Biotherapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.
100% more capital invested
Capital invested by funds: $1K → $2K (+$1K)
50% less funds holding
Funds holding: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IP
1
Intellectus Partners
San Francisco,
California
| $2K | +$3.26K | +10,750 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| – | -$1K | -1,508 | Closed |
|
NWBOW Hedge Fund Activity: Q4 2016 in Review
1 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. (NWBOW) for Q4 2016, worth a combined $2K — up 100% from $1K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NWBOW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $1K sold.
- 1 institutional investor held Northwest Biotherapeutics, Inc. (NWBOW) as of Q4 2016, down from 2 in Q3 2016.
- Funds reported $2K of Northwest Biotherapeutics, Inc. stock for Q4 2016, up 100% quarter-over-quarter.
- 1 fund opened new Northwest Biotherapeutics, Inc. positions in Q4 2016 and 2 closed out, a net change of -1 holder.
- The largest Northwest Biotherapeutics, Inc. seller in Q4 2016 was UBS Group, an estimated $1K sold.
Based on aggregated 13F filings for Q4 2016.